Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy: data from the BIOBADASER registry
14/08/2023
J. Molina Collada1,2, F. Sánchez-Alonso3 , C. Bohórquez4 , C. Diaz-Torne5 , C. Perez-Garcia6 , J. M. Blanco7 , P. Vela-Casasempere8 , I. Castrejon1,2.
EULAR 2022
DOI: 10.1136/annrheumdis-2022-eular.5030
https://ard.bmj.com/content/81/Suppl_1/88.2